1567. Utilization of T2Candida Panel for the rapid detection of Candida species in a large community hospital
Session: Poster Abstract Session: Mycology: Diagnostic
Friday, October 28, 2016
Room: Poster Hall
Background: The T2Candida Panel is a newly FDA approved diagnostics conducted from whole blood that detects 5 Candida species: C. albicans, C. tropicalis, C. parapsilosis, C. krusei, and C. glabrata in 3 to 5 hours without the need for blood cultures. The purpose of this study is to implement and evaluate the utilization of T2Candida Panel in a large community hospital.

Methods: Prospective, observational analysis included 160 patients who met our specified criteria. The T2Candida Panel was restricted to Infectious Disease (ID) and Oncology physicians’ use for specific patient populations, including with: febrile neutropenia; ICU stay for >72 hours, central venous catheter, recent antibiotics, acute pancreatitis, recent major surgery, TPN, renal failure/hepatic failure, corticosteroids and unexplained fever.

Results: Patients mean age 61 years, 52% were male. Most common comorbidities included DM, CKD, and COPD. Candidemia risk factors included: 27.2% malnutrition/TPN, 32.4% renal failure, 27.2% intra-abdominal infection/surgery, 40.4% immunocompromised (cancer, chemotherapy, chronic steroids, febrile neutropenia), 51.4% CVC/PICC line. 69% of the patients were in the ICU. Of the 160 T2 tests evaluated, 8.8% were positive. The resulting species were as follows: 6 C. albicans/tropicalis, 7 C. parapsilosis, and 1 resulted with both C. albicans/tropicalis and C. parapsilosis. Only 36% of the positive T2 patients had a positive corresponding blood culture with 100% concordance. There was no positive blood culture for candida species and negative T2 test. The mean duration of therapy (DOT) of micafungin and time to de-escalation for negative T2 patients was 4 days and 42.6 hours respectively, equating to about $280 per patient. When results were divided according to the 3 ID physician groups, the mean DOT for negative T2 patients were as follows: 1.1, 5.6, and 3.4 days. The time to de-escalation/discontinuation of therapy for the 3 physician groups were 15, 52.4, and 54 hours.

Conclusion: The T2Candida panel has demonstrated greater sensitivity to detect Candidemia at our facility and has provided a much faster time of antifungal treatment modification, but inconsistent utilization of the test results between different ID physicians were observed.

Hayley Kateon, PharmD, BCPS1, Jonathan Edwards, PharmD, BCPS AQ-ID1, Adam Sawyer, PharmD, BCPS, BCCCP1, Jesse Ross, Medical student2 and Ali Hassoun, MD FIDSA FACP2, (1)Huntsville Hospital, Huntsville, AL, (2)Alabama Infectious Diseases Center, Huntsville, AL


H. Kateon, None

J. Edwards, None

A. Sawyer, None

J. Ross, None

A. Hassoun, None

See more of: Mycology: Diagnostic
See more of: Poster Abstract Session

Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.